Pre-morbid Conduct Disorder symptoms are associated with cannabis use among individuals with a first episode of psychosis

Malcolm, Charlotte; Picchioni, Marco; Forti, Marta Di; Sugranyes, Gisela; Cooke, Elizabeth; Joseph, Candice; McQueen, Grant; Paparelli, Alessandra; Stilo, Simona A.; O’Connor, Jennifer; Morgan, Craig; Murray, Robin M.; Hodgins, Sheilagh

doi:10.1016/j.schres.2010.11.025

Cited by 27 publications

(11 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among children who are vulnerable to schizophrenia, cannabis further alters the developing brain as it transitions to a disordered state. In a sample of individuals experiencing their first episode of psychosis, we observed that the number of CD symptoms prior to age 14 was associated with lifetime cannabis use and with use of cannabis prior to age 14 (Malcolm et al 2011). In a sample of individuals experiencing their first episode of psychosis, we observed that the number of CD symptoms prior to age 14 was associated with lifetime cannabis use and with use of cannabis prior to age 14 (Malcolm et al 2011).…”

Section: Cannabis Usementioning

confidence: 76%

Neuroscience of Aggression

Miczek¹,

Meyer‐Lindenberg²

2014

Current Topics in Behavioral Neurosciences

View full text Add to dashboard Cite

Current Topics in Behavioral Neurosciences provides critical and comprehensive discussions of the most significant areas of behavioral neuroscience research, written by leading international authorities. Each volume offers an informative and contemporary account of its subject, making it an unrivalled reference source. Titles in this series are available in both print and electronic formats.With the development of new methodologies for brain imaging, genetic and genomic analyses, molecular engineering of mutant animals, novel routes for drug delivery, and sophisticated cross-species behavioral assessments, it is now possible to study behavior relevant to psychiatric and neurological diseases and disorders on the physiological level. The Behavioral Neurosciences series focuses on "translational medicine" and cutting-edge technologies. Preclinical and clinical trials for the development of new diagnostics and therapeutics as well as prevention efforts are covered whenever possible.More information about this series at

show abstract

Section: Cannabis Usementioning

confidence: 76%

Neuroscience of Aggression

Miczek¹,

Meyer‐Lindenberg²

2014

Current Topics in Behavioral Neurosciences

View full text Add to dashboard Cite

show abstract

“…There is, however, some evidence that high CAPE scores associated with acute cannabis intoxication are also a reflection of psychosis proneness [42]. Also, although measures were available for demographic factors and substance use, residual confounding by extensive behavioural and psychopathological factors such as attention‐deficit hyperactivity disorder, externalizing behaviour and conduct disorder [21,43–45] cannot be ruled out. Future research should include these factors.…”

Section: Discussionmentioning

confidence: 99%

Cannabis use and subclinical positive psychotic experiences in early adolescence: findings from a Dutch survey

et al. 2011

View full text Add to dashboard Cite

show abstract

“…The sample analysed comprised patients with first-episode psychosis from the Genetics and Psychosis (GAP) study. 12 , 13 , 14 All cases were recruited between 2004 and 2010 at their first presentation to the South London and Maudsley NHS Foundation Trust: a large, near-monopoly provider of mental-health care to a geographic catchment of ~1.2 million residents in southeast London. All GAP participants were aged between 18 and 65 years, and met ICD10 diagnostic criteria for functional psychosis (F20–29 or F30–33).…”

Section: Methodsmentioning

confidence: 99%

Associations between the schizophrenia susceptibility gene ZNF804A and clinical outcomes in psychosis

et al. 2015

View full text Add to dashboard Cite

We sought to test the hypothesis that the rs1344706 A allele will be associated with worse clinical outcome in first-episode psychosis. A data linkage was set up between a large systematic study of first-episode psychosis and an electronic health-record case register at the South London and Maudsley NHS Foundation Trust—a large provider of secondary mental-health care. A sample of 291 patients, who presented with a first psychotic episode (ICD10 diagnoses F20–29 or F30–33) and in whom the rs1344706 genotype had been assayed, were followed to examine the duration of mental-health in-patient care during the 2 years following first service contact, as a primary outcome. Secondary outcome measures were whether or not an in-patient episode occurred and the number of in-patient episodes during this period. A strong association was found between the number of rs1344706 A alleles and the cumulative duration of mental-health in-patient stay over the 2 years since initial presentation. In the 84.2% who experienced an in-patient episode during this period, the mean duration of admission was an additional 38 days for each A allele increment. Therefore, in addition to its potential role as a risk factor for psychosis, the ZNF804A rs1344706 A allele is associated with worse clinical outcome.

show abstract

Pre-morbid Conduct Disorder symptoms are associated with cannabis use among individuals with a first episode of psychosis

Cited by 27 publications

References 33 publications

Neuroscience of Aggression

Neuroscience of Aggression

Cannabis use and subclinical positive psychotic experiences in early adolescence: findings from a Dutch survey

Associations between the schizophrenia susceptibility gene ZNF804A and clinical outcomes in psychosis

Contact Info

Product

Resources

About